Vincristine Sulfate Liposome

硫酸长春新碱脂质体

Report date: 2026/05/26 20:00:28

Base Information

Drug NameVincristine Sulfate Liposome
Drug Alias NameLeurocristine sulfate liposome长春新碱硫酸盐脂质体Vincristinum liposome硫酸醛基长春碱脂质体Vincosid liposome +[8] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionTubulin polymerisation inhibitors
TargetsTubulin
Therapy Area/IndicationsUterine Cervical NeoplasmsSmall Cell Lung CarcinomaTesticular Neoplasms +[11] 
Global Approved IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2012/08/09
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAcrotech Biopharma Llc
China Registration ClassN/A

Develop Information

Active CompaniesNanjing Luye Pharmaceutical Co LtdNanjing Kanghai Pharmaceutical Co LtdCASI Pharmaceuticals (China) Co Ltd
Inactive CompaniesAcrotech Biopharma Llc
Active IndicationsPrecursor Cell Lymphoblastic Leukemia-Lymphoma
Inactive IndicationsUterine Cervical NeoplasmsSmall Cell Lung CarcinomaTesticular Neoplasms +[10] 

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG